fashion -WSS

fashion

author：comprehensive 2025-09-28 08:53:35 - browse：812

Silhouette of a medical staff, followed by another, running pushing a nursing bed. Two people talk next to the hurrying staff in the corridor — coverage from STAT — Adobe

There’s ample evidence that private equity buyouts in health care drive up costs. A new study shows quality declines, too.

Hospitals acquired by private equity saw a 25% uptick in adverse events compared with controls, according to a new study released today in the Journal of the American Medical Association. The findings add to an accumulating body of literature underscoring the harm that occurs when financial investors take over health care providers — not only hospitals, but nursing homes, hospice care, and physician practices.

Even after adjusting their findings to be more conservative, the researchers on the JAMA study found that all of the hospital-acquired conditions they studied increased three years after a private equity acquisition compared to control hospitals. Not all of the increases were statistically significant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Prior authorization will have to move faster under new Biden rule

focus

WSS

Research misconduct: Proposed new rules face resistance

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Gene therapy’s promise and the high cost of hope

Kidney transplant patients stopped immunosuppressants in trial

The tragedy of Johnson & Johnson’s Covid vaccine

Live blog: Hearing on CRISPR

hotspot

fashion

knowledge

State Dept. review finds Biden bears some blame for Afghanistan failures

The tragedy of Johnson & Johnson’s Covid vaccine

The cancer drug shortage isn’t new — and neither are the solutions

Think you might have Covid

Hollywood unions extend contract negotiations for actors

My yearlong odyssey to get my son’s ADHD medication covered

How one medical school became remarkably diverse

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Psychedelics group wrestles with new pharma identity

What is microchimerism and how does it affect maternal health?

focus

How to convince healthy people to buy insurance

NIH director takes cautious approach to Biden drug pricing priority

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Explaining an after

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Independent physicians launch a new lobbying group

focus

focus

knowledge

focus